Eli Lilly, Novo Nordisk Make GLP-1 Medications Available Through Mangoceuticals Platform
MT Newswires Live
Nov 13
Eli Lilly (LLY) and Novo Nordisk (NVO) have entered into a partnership with Mangoceuticals (MGRX) to launch two integrated programs that provide direct access to the two firms' GLP-1 medications, Mangoceuticals said Thursday.
MangoRx Direct and PeachesRx Direct will provide access to Lilly's Zepbound and Novo Nordisk's Wegovy, respectively, Mangoceuticals said.
Through MangoRx and PeachesRx's secure telehealth platform, customers will receive virtual consultations with board-certified providers, personalized weight management treatment plans, ongoing clinical monitoring and support, and fulfillment of the medications, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.